Self-monitoring of blood glucose levels among pregnant individuals with gestational diabetes: a systematic review and meta-analysis

Ping Teresa Yeh¹, Caitlin Elizabeth Kennedy¹, Dong Keun Rhee¹, Chloe Zera², Özge Tunçalp³,
 Briana Lucido³, Rodolfo Gomez Ponce de Leon⁴, Manjulaa Narasimhan^{3*}

- ³ ¹Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore,
- 4 Maryland, USA.
- ⁵ ²Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Beth Israel
- 6 Deaconess Medical Center, Harvard Medical School.
- 7 ³Department of Sexual and Reproductive Health and Research, World Health Organization, includes
- 8 the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and
- 9 Research Training in Human Reproduction HRP, Geneva, Switzerland.
- 10 ⁴Latin American Center of Perinatology, Women and Reproductive Health PAHO/WHO,
- 11 Montevideo, Uruguay.
- 12 * Correspondence:
- 13 Manjulaa Narasimhan
- 14 Department of Sexual and Reproductive Health and Research
- 15 UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme
- 16 World Health Organization
- 17 20 Avenue Appia, 1211 Geneva 27, Switzerland
- 18 narasimhanm@who.int
- 19 Keywords: self-monitoring1, blood glucose2, diabetes3, pregnancy4, pre-eclampsia5, self-care6.
- 20 1 Abstract
- 21 Introduction: The World Health Organization (WHO) recommends treatment and management of
- 22 gestational diabetes (GD) through lifestyle changes, including diet and exercise, and self-monitoring
- 23 blood glucose (SMBG) to inform timely treatment decisions. To expand the evidence base of WHO's
- 24 guideline on self-care interventions, we conducted a systematic review of SMBG among pregnant
- 25 individuals with GD.
- Setting: We searched for publications through November 2020 comparing SMBG with clinic-based
 monitoring during antenatal care (ANC) globally.
- 28 **Primary and secondary outcome measures:** We extracted data using standardized forms and
- 29 summarized maternal and newborn findings using random effects meta-analysis in GRADE evidence
- 30 tables. We also reviewed studies on values, preferences, and costs of SMBG.
- 31 **Results:** We identified 6 studies examining SMBG compared to routine ANC care, 5 studies on
- 32 values and preferences, and 1 study on costs. Nearly all were conducted in Europe and North
- 33 America. Moderate-certainty evidence from 3 randomized controlled trials (RCTs) showed that
- 34 SMBG as part of a package of interventions for GD treatment was associated with lower rates of

- 35 preeclampsia, lower mean birthweight, fewer infants born large for gestational age, fewer infants
- 36 with macrosomia, and lower rates of shoulder dystocia. There was no difference between groups in
- 37 self-efficacy, preterm birth, C-section, mental health, stillbirth, or respiratory distress. No studies
- 38 measured placenta previa, long-term complications, device-related issues, or social harms. Most end-
- 39 users supported SMBG, motivated by health benefits, convenience, ease of use, and increased
- 40 confidence. Health workers acknowledged SMBG's convenience but were wary of technical
- 41 problems. One study found SMBG by pregnant individuals with insulin-dependent diabetes was
- 42 associated with decreased costs for hospital admission and length of stay.
- 43 Conclusion: SMBG during pregnancy is feasible and acceptable, and when combined in a package
- 44 of GD interventions, is generally associated with improved maternal and neonatal health outcomes.
- 45 However, research from resource-limited settings is needed.
- 46 Systematic review registration number: PROSPERO CRD42021233862
- 47 2 Manuscript

48 **2.1 Introduction**

- 49 Gestational diabetes (GD) is defined as glucose intolerance resulting in clinical hyperglycemia with
- 50 onset or first recognition during pregnancy.[1, 2] Hyperglycemia during pregnancy is associated with
- adverse short-term and long-term maternal and newborn health outcomes. Self-management of GD
- 52 through lifestyle modification, including diet and exercise, is considered first-line treatment by health
- 53 workers and several professional associations.[3-5] One component of GD self-management is self-
- 54 monitoring of blood glucose (SMBG) levels, which is used clinically to monitor the effectiveness of
- 55 lifestyle changes, guide intensification of treatment, and inform ANC.
- 56 This systematic review sought to examine the evidence for SMBG compared with monitoring of
- 57 blood glucose levels by health workers within the ANC (clinic) setting. We conducted this systematic
- review in the context of expanding the evidence base of the World Health Organization (WHO)
- 59 guideline on self-care interventions for health,[6] which includes several recommendations on self-
- 60 care interventions during pregnancy, childbirth and post-natal care.[7, 8] WHO's 2020 "Package of
- 61 Essential Noncommunicable Disease Interventions for Primary Health Care" recommends 'non-
- 62 pharmacological' treatment for management of type 2 diabetes.[9] This could be considered self-
- 63 care, though it does not specify how/by whom diabetes should be diagnosed or monitored.
- 64 Furthermore, self-monitoring may be a feasible approach when health services are disrupted such as
- 65 in emergency or humanitarian settings. In the context of maintaining essential health services during
- 66 the COVID-19 pandemic, WHO recommends creation of self-management plans for diabetes, if
- 67 appropriate, supported by health workers.[10]

68 2.2 Methods

- 69 This review addressed the following overarching question: Should SMBG among pregnant women
- and other pregnant people¹ with GD be made available in addition to clinic check-ups? Per the WHO

¹ While a majority of persons who are or can get pregnant are cisgender women, who were born and identify as female, transgender men and other gender diverse people may have the reproductive capacity to get pregnant. Therefore, the WHO guideline on self-care interventions which references the findings of this review uses language that is inclusive of all these experiences ("pregnant individuals"). In this manuscript, we use the term

- 71 guideline development process which incorporates multiple aspects of evidence,[11] we reviewed the
- extant literature in three areas relevant to this question: effectiveness of the intervention (what is the
- 73 impact on the outcomes of interest when comparing SMBG to glucose monitoring at clinic check-ups
- for pregnant individuals with GD?), values and preferences of end users and health workers (what do
- 75 patients and health workers think of SMBG?), and cost information (what are the costs (to the patient
- and to the health system) of SMBG?).
- 77 We followed Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA)
- 78 guidelines,[12] and we registered the protocol on the International Prospective Register of Systematic
- 79 Reviews (PROSPERO registration number CRD42021233862). Ethical approval was not required
- 80 for this systematic review, since all data came from published articles.

81 Effectiveness review

- 82 The effectiveness review was designed according to the PICO format as follows, through
- 83 consultation with the WHO staff and expert group as part of the WHO guideline development
- 84 process,[11] focusing on the aspect of self-monitoring versus clinic monitoring:
- 85 **Population:** Pregnant women and other pregnant people diagnosed with GD
- 86 Intervention: SMBG (either by the pregnant person or by another layperson, such as a family
- 87 member) Note: Although many products, devices, and mobile applications can be used to monitor
- 88 blood glucose levels, we defined SMBG as home-based use of finger-prick devices, continuous
- 89 glucose monitoring (including real-time), flash glucose monitoring, or urine dipstick for glucose
- 90 testing.
- 91 Comparison: Clinic blood glucose monitoring by health workers during ANC contacts only

92 **Outcomes:**

- 93 Maternal:
- 94 (1) Preterm labor
- 95 (2) Caesarean section (including emergency C-section)
- 96 (3) Long-term progression to type 2 diabetes or other metabolic disorders
- 97 (4) Placenta previa
- 98 (5) Hypertensive disorders of pregnancy (pre-eclampsia) or eclampsia
- 99 (6) Self-efficacy, self-determination, autonomy, and empowerment
- 100 (7) Device-related issues (e.g. test failure, problems with manufacturing, packaging,
 101 labelling, or instructions for use)
- 102 (8) Follow-up care with appropriate management
- 103 (9) Mental health and well-being (e.g. anxiety, stress, self-harm)
- 104(10)Social harms (including discrimination, intimate partner violence, stigma), and whether105these harms were corrected/had redress available
- 106 Fetal/newborn:

[&]quot;pregnant women and other pregnant people" to include the preferred terminology of pregnant parents who use words other than women.

- 107 (1) Birth weight/size for gestational age (including macrosomia)
- 108 (2) Respiratory distress syndrome
- 109 (3) Stillbirth or perinatal death
- 110 (4) Shoulder dystocia

111 Inclusion criteria

- 112 To be included in the review, an article must have met the following criteria:
- Study design that compared SMBG to clinic monitoring of blood glucose levels by health
 workers during ANC visits. This includes both randomized controlled trials, non-randomized
 controlled trials and comparative observational studies (including prospective controlled
 cohort studies, cross-sectional studies, controlled before-after studies and interrupted time
 series) that compare individuals who received the intervention to those who did not.
- 118 2) Measured one or more of the outcomes listed above
- 119 3) Published in a peer-reviewed journal
- 120 No restrictions were placed based on location of the intervention. No language restrictions were used
- 121 on the search. Articles in English, French, Spanish, and Chinese were coded directly; articles in other
- 122 languages were translated.

123 Search strategy

- 124 The following electronic databases were searched through the search date of November 11, 2020:
- PubMed, CINAHL, LILACS, and EMBASE using the following search string (designed for Pubmedand adapted for the other databases).
- ("glucose tolerance test"[Mesh] OR "oral glucose tolerance test"[tiab] OR "OGTT"[tiab] OR
 "blood glucose"[Mesh] OR "blood glucose"[tiab] OR "blood sugar"[tiab] OR "diabetes"[tiab]
 OR "gestational diabetes"[mesh] OR "gestational diabetes mellitus"[tiab] OR "glycemic
- 130 index"[Mesh] OR "continuous glucose monitoring"[tiab] OR "glucose monitoring
- 131 technique"[tiab] OR "glycemic control"[tiab] OR "flash glucose monitoring"[tiab])
- 132 AND
- (pregnancy [Mesh] OR pregnancy [tiab] OR pregnant [tiab] OR peri-natal [tiab] OR perinatal
 (tiab] OR antenatal [tiab] OR maternal [tiab])
- 135 AND
- 136 ("self care"[Mesh] OR "self-care"[tiab] OR "self-monitoring"[tiab] OR "self-
- 137 management"[tiab] OR "self-monitor"[tiab] OR "self-manage"[tiab] OR "self-
- 138 monitored"[tiab] OR "self-managed"[tiab] OR "self-evaluate"[tiab] OR "self-evaluating"[tiab]
- 139 OR "self-evaluation"[tiab] OR "self-test"[tiab] OR "self-testing"[tiab] OR "home"[tiab] OR
- 140 "pharmacy"[tiab])
- 141 Secondary reference searching was conducted on all studies included in the review and
- 142 relevant reviews.[13-18] We also searched for ongoing randomized controlled trials (RCTs)
- 143 through clinicaltrials.gov, the WHO International Clinical Trials Registry Platform, the Pan
- 144 African Clinical Trials Registry, and the Australian New Zealand Clinical Trials Registry. In

- 145 addition, we searched the Cochrane Database of Systematic Reviews for potentially relevant
- 146 articles cited in their reviews. Finally, selected experts in the field were contacted to identify
- 147 additional articles not identified through other search methods.
- 148 Titles, abstracts, citation information, and descriptor terms of citations identified through the
- search strategy were screened by a member of the senior study staff. Full text articles were
- 150 obtained of all selected abstracts and two independent reviewers assessed all full-text articles
- 151 for eligibility to determine final study selection. Differences were resolved through consensus.

152 Data management and analysis

- 153 Data were extracted independently by two reviewers using standardized data extraction forms.
- 154 Differences in data extraction were resolved through consensus and referral to a senior study
- team member from WHO when necessary.
- 156 The following information was gathered from each included study:
- Study identification: Author(s); type of citation; year of publication
- Study description: Study objectives; location; population characteristics; definition
 of/diagnostic criteria for GD used in the study; type of blood glucose monitoring; description
 of self-monitoring access; description of any additional intervention components (e.g. any
 education, training, support provided); study design; sample size; follow-up periods and loss
 to follow-up
- Outcomes: Analytic approach; outcome measures; comparison groups; effect sizes;
 confidence intervals; significance levels; conclusions; limitations
- 165 For RCTs, risk of bias was assessed using the Cochrane Collaboration's tool for assessing risk of
- 166 bias.[19] For studies that were not randomized trials but were comparative, study rigor was
- assessed using the Evidence Project 8-item checklist for intervention evaluations.[20] Data
- 168 were analyzed according to coding categories and outcomes. Where there were multiple
- 169 studies reporting the same outcome, meta-analysis was conducted using random-effects
- 170 models to combine risk ratios (RRs) or mean differences (MDs) with the program
- 171 Comprehensive Meta-Analysis (CMA).
- 172 For each PICO outcome category, data were summarized in a GRADE Evidence Profile table
- 173 using GRADEPro, prioritizing RCT data over observational data where available.
- 174 All analyses were stratified by the following categories/subgroups, where possible:
- Home monitoring (self, layperson, community health worker) vs. clinic monitoring outside of
 ANC (ambulatory, hospitalized, or additional to standard antenatal clinic visits)
- Type of glucose monitor
- Prior risk of (gestational) diabetes
- Vulnerabilities (i.e. obesity, age, poverty, disability, rural/urban, literacy/education level)
- High-income versus low or middle-income countries

181 **Complementary reviews**

- 182 We conducted complementary reviews to examine the values and preferences of end-users and health
- 183 workers and costs related to SMBG. We used the same search strategy as the effectiveness review to

- 184 identify studies to be included in these reviews. These studies could have been qualitative or
- 185 quantitative in nature, but had to present primary data collection; think pieces and review articles
- 186 were not included. We summarized this literature qualitatively and organized findings by study
- 187 design and methodology, location, and population.
- 188 Values and preferences review. We focused on studies examining the values and preferences of
- 189 pregnant women and other pregnant people who were self-monitoring blood glucose levels or who
- 190 were potential candidates for such self-monitoring, but we also included studies examining the values
- and preferences of health workers. We considered issues related to age of availability, informed
- 192 decision-making, coercion, and seeking redress in this section; this included the effects of stock-outs
- 193 or availability of glucose monitors.
- 194 <u>Cost review.</u> We included studies in this review if they presented primary data comparing costing,
- 195 cost-effectiveness, cost-utility, or cost-benefit of the intervention and comparison listed in the PICO
- 196 question above, or if they presented cost-effectiveness of the intervention as it related to the PICO
- 197 outcomes listed above. This included both cost to the health system and cost to the end-user. Cost
- 198 literature were classified into four categories: health sector costs, other sector costs, end-user/family
- 199 costs, and productivity impacts.

200 2.3 Results

201 Our database search yielded 2787 records, and another 10 were identified through hand-searching

- and secondary searching (Figure 1). Of the 1871 unique records, we retained 78 for full-text review.
- 203 Ultimately, we included 6 studies in the effectiveness review, 5 in the values and preferences review,
- and 1 in the cost review.
- 205 Figure 1. PRISMA flowchart for the search and screening process.

206 Effectiveness review

- 207 For the effectiveness review, we identified 6 studies meeting the inclusion criteria: 3 RCTs and 3
- 208 observational studies.[21-26] The two larger RCTs (approximately 500 individuals per arm)
- 209 compared SMBG as part of a package of interventions for GD treatment to routine care during
- antenatal contacts on clinical and healthcare utilization outcomes; one small RCT compared SMBG
- with periodic monitoring during prenatal visits on pregnancy and psychosocial outcomes (Table 1).
 While they did not specify the specific approach to glucose surveillance in the clinic setting, and
- While they did not specify the specific approach to glucose surveillance in the clinic setting, and while the results could not be disaggregated by intervention component, we opted to include these
- studies in the analysis as the closest available evidence for our PICO question. Both intervention and
- control groups ultimately received blood glucose monitoring and appropriate follow-up/treatment for
- GD; the difference was in self- versus clinic-monitoring. The 3 observational studies presented the
- same outcomes as the RCTs; therefore, to assess the highest-certainty evidence for each PICO
- 218 outcome category, we included RCT data in the GRADE Evidence Profile (Table 2). Findings
- summarized in Table 2 represent pooled results from meta-analysis where multiple studies measured
- the same outcome, and the effect size of single studies where no other studies measured a specific
- outcome in a similar way. Meta-analysis results are presented in Figure 2. Given the small number of
- studies presenting outcome data, no further stratifications from our *a priori* list were possible.
- 223 Table 1. Description of included studies in the effectiveness review (RCTs)
- 224 Table 2. GRADE Evidence Profile

225 Figure 2. Forest plots and summary statistics from meta-analysis.

226 Maternal Outcomes

227 Moderate-certainty evidence from two RCTs demonstrated that SMBG as part of a package of

interventions for GD treatment led to lower rates of preeclampsia (RR 0.61, 95% CI 0.46-0.81,

Figure 2A).[22, 26] There was no difference on cesarean delivery rates (Figure 2B), with a pooled

- rate of 29.2% in the group that was treated, as compared to 32.6% in the untreated controls (RR 0.92,
- 231 95% CI 0.72-1.18), based on moderate- to low-certainty evidence from three RCTs.[22, 25, 26] One
- trial which disaggregated C-section outcomes by elective C-section and emergency C-section also
- found no difference between groups.[22] This package of interventions was not associated with
- gestational age at delivery[25, 26] or risk for preterm delivery[22] (RR 0. 81, 95% CI 0.56-1.18); this avidence was graded as low to moderate containty
- evidence was graded as low- to moderate-certainty.
- 236 In a small RCT in the United States, Homko and colleagues found no impact of SMBG as part of a
- package of interventions on self-efficacy based on self-empowerment score at 37 vs 33 weeks;[25]
- this evidence was graded as low certainty because of lack of blinding and the very small sample size.
- 239 One RCT conducted in Australia and the United Kingdom showed SMBG as part of a package of
- 240 interventions had no impact on validated questionnaire measures of mental health or anxiety.[22]

241 Fetal/neonatal Outcomes

- 242 Moderate-certainty evidence from 3 RCTs demonstrates that SMBG as part of a package of
- 243 interventions was associated with changes in fetal growth, including lower mean birthweight (-
- 244 126 g, 95% CI -176 to -76 g, Figure 2C) as well as lower risk for large for gestational age
- 245 birthweight (RR 0.58, 95% CI 0.46 to 0.72, Figure 2D) and macrosomia (RR 0.44, 95% CI 0.34 to
- 246 0.57, Figure 2E) when compared to routine care during ANC contacts.[22, 25, 26] Two of these
- 247 RCTs also demonstrated SMBG as part of a package of interventions was associated with lower
- rates of shoulder dystocia (RR 0.41, 95% CI 0.22 to 0.76, Figure 2F).[22, 26] There was no
- difference between groups for stillbirth rate[22, 26] (Figure 2G, low-certainty) or respiratory
- distress syndrome[22, 25, 26] (Figure 2H, very-low-certainty).
- 251 *Healthcare Utilization*
- 252 Crowther and colleagues quantified the impact of SMBG as part of a package of interventions for
- 253 GD treatment on multiple measures of healthcare utilization.[22] In this study, both
- 254 participants and health workers were blinded to the diagnosis of GD at randomization, and
- 255 therefore treatment was, as expected, associated with more physician clinic visits and visits
- with dietitians and diabetes educators. Assignment to the treatment arm had no impact on
- 257 antenatal hospital admissions.
- 258 No studies reported other quantitative comparative outcomes of interest for the effectiveness
- review, including long-term complications (such as both maternal and child type 2 diabetes,
- 260 hypertension, or other metabolic disorders), device-related issues (e.g. test failure, problems
- with manufacturing, packaging, labeling, instructions), or social harms (e.g. discrimination,
- 262 intimate partner violence, stigma).

263 Values and Preferences Review

- 264 Five feasibility studies reported in 6 articles presented values and preferences data for specific
- blood glucose management systems (Table 3).[27-32] These studies (3 quantitative and 3
- 266 qualitative) all took place in high or upper-middle income countries: Canada, United Kingdom,
- 267 Norway, Spain, and Thailand.
- 268 Table 3. Description of studies presenting values and preferences data
- 269 Overall, end-users found SMBG acceptable and even beneficial for a variety of reasons.
- 270 Participants appreciated the technical convenience of using a smartphone for SMBG, which
- 271 made recording and sharing blood glucose level readings easy,[29, 30] allowed for receiving
- feedback in real-time,[31] and kept important GD-related information handy as a resource.[31]
- Most believed that successful SMBG led to delivering healthy infants.[31, 32] However, this
- overall positive response appeared to be mostly from those who incorporated smartphone use
- in self-monitoring: one study which required participants use a glucometer and log book to
- 276 record their blood glucose level values found only 6-7% of the surveyed end-users said that 277 SMPC was convenient [27]
- 277 SMBG was convenient.[27]
- 278 Among end-users who self-monitored their blood glucose via smartphone, there was general
- consensus on the ability of SMBG to improve their confidence about health or self-care. Beyond
- 280 finding SMBG useful and convenient, most stated they would recommend SMBG to other

281 pregnant women and other pregnant people with GD.[30] End-users also found that SMBG

- 282 increased their self-awareness and knowledge of their health status, amplifying their ability to
- 283 effectively manage blood glucose levels during and after pregnancy.[31]
- 284 However, end-users also noted some concerns about SMBG. Some were frustrated with
- technical issues with the smartphone application: sometimes the application automatically
- transferred blood glucose values and registered wrong values.[31] Others expressed hesitation
- about the pain that comes with finger-pricking, though this dissipated over time and with
- experience.[32] When health workers lacked interest in the smartphone application, end-users
- were discouraged from continuing SMBG; most considered SMBG as a supplement to and not a
- 290 replacement for usual ANC visits.[31]
- 291 One study in Norway reported values and preferences about SMBG from the health worker
- 292 perspective.[28] Most participants agreed that SMBG through a smartphone application could
- 293 help pregnant women and other pregnant people self-manage GM and found it useful for its
- 294 convenience over paper-recording, especially given that modern technological progress would
- 295 make app-based SMBG a more common practice over time. In addition, midwives and nurses
- reported liking the fact that the application could be resourceful for patients by providing
- helpful, credible health-related information to complement the SMBG records. However, some
- also expressed concerns that using the application alone may not allow patients to convey their emotion to their health care team, which could negatively affect the patient-provider
- emotion to their nearth care team, which could negatively affect the patient-provider relationship.

301 **Cost Review**

- 302 No studies investigated the economic effects of SMBG in people with GD. One study reported
- 303 economic effects of SMBG by patients with insulin-dependent diabetes during pregnancy
- 304 (Orange County, California, USA).[33] Though this was a different study population than our
- 305 population of interest, we used this study as indirect evidence for individuals with GD. Patients

306 in the group using the reflectance colorimeter (SMBG) spent an average of 1.3 days in the

307 hospital at a total average cost of US \$593.00 as compared with the control group (conventional

308 outpatient), who were hospitalized for an average of 3.8 days at an average of US \$1,732.80.

309 Only two of the nine patients in the meter group required admission as compared to five of the

310 nine patients in the control group.

311 2.4 Discussion

312 This review attempted to answer the question of the value of SMBG for pregnant women and 313 other pregnant people with GD. All three RCTs included in the effectiveness review compared 314 SMBG as part of a package of interventions for GD treatment to routine care during ANC 315 contacts. While they did not specify the specific approach to glucose surveillance in the clinic 316 setting such that none of the comparison groups were explicitly aligned with the comparator in 317 our PICO question but were approximations, and while the results could not be disaggregated 318 by intervention component, the results highlight the value of SMBG as part of a larger program 319 of treatment for GD. These studies showed that SMBG, in combination with other interventions 320 for GD, was associated with maternal benefit, specifically lower risk of preeclampsia, as well as 321 fetal benefits, including lower mean birthweight, fewer infants born large for gestational age, 322 fewer infants with macrosomia, and lower rates of shoulder dystocia. In studies reporting end-323 users' values and preferences, pregnant women and other pregnant people found SMBG 324 acceptable and recognized benefits including convenience, ease of use, and increased

325 confidence in managing their own health. Although we found no cost studies specifically on

326 SMBG by individuals with GD, one study among pregnant women and other pregnant people

327 with insulin-dependent diabetes found modest cost savings associated with SMBG.

328 Our findings must be interpreted in the context of limited available data. None of the

329 effectiveness studies we identified included a control group with monitoring in the clinic

330 setting, but rather had untreated "mild" GD receiving routine ANC. Inclusion of control

331 participants with untreated GD likely exaggerates the impact of SMBG; however, we were

unable to find any studies comparing SMBG to periodic monitoring in the ANC setting. While we

hypothesize that isolated blood glucose monitoring in a clinic setting has limited utility, it is

334 possible that periodic checks in the clinic setting have some benefit beyond no treatment at all 335 given the likelihood of identifying the most overt hyperglycemia. However, participants with

335 given the likelihood of identifying the most overt hyperglycemia. However, participants with 336 overt hyperglycemia on glucose screening tests were excluded from the RCTs included in this

337 analysis.

338 In addition, though insulin therapy and dietary behavior modifications are both appropriate 339 responses to the findings from blood glucose monitoring, because the included studies did not 340 disaggregate data by the follow-up given after the monitoring (self vs clinic) step, we were not 341 able to compare the effects of pharmacological intervention for GD in this review. Of the six 342 included studies in the effectiveness review, five mentioned insulin therapy. Two of the three 343 RCTs used in the effectiveness review listed in Table 1 compared SMBG (plus nutrition/diet counseling and insulin therapy if required) to routine prenatal care and did not disaggregate 344 345 outcome effects by exposure to different components of the multi-component intervention, [22, 346 26] and the third RCT compared SMBG to clinic-monitoring in the context of diet-treated GD, 347 though if a participant failed to meet metabolic targets they would start insulin.[25] Of the 348 three observational studies, one study in the Czech Republic and another in Denmark 349 compared SMBG to clinic-monitoring among women with insulin-treated GD,[21, 23] so both

- 350 intervention and treatment groups received pharmacological intervention, and the third study
- in the USA compared SMBG to clinic-monitoring among diet-treated GD and explicitly excluded
- women who were initiated on insulin from the analysis.[24]
- 353 A strength of the review was the inclusion not only of effectiveness studies, but also of studies
- 354 looking at costs and at values and preferences of patients and health workers. Costs to the
- 355 patient, the health system, and society more broadly are an important consideration for any
- 356 potential monitoring intervention. Potential drawbacks of SMBG as part of treatment of GD
- 357 include increased healthcare utilization. One small study suggested potential cost savings;
- 358 however, no studies examined out-of-pocket costs to individuals versus health system costs.
- 359 Across multiple settings, values and preferences were generally positive towards SMBG,
- 360 despite a few study participants noting inconveniences or frustrations with the
- technology/device. Studies generally pointed towards approval of expanded use of SMBG.
- 362 All of the studies included in the meta-analysis were conducted in high-income countries; only
- 363 one values and preferences study was conducted outside of the United States and Europe (in
- 364 Thailand). Health systems differ widely in their ability to provide care to individuals with GD,
- and data from a wider range of settings on effectiveness, values and preferences, and cost of
- 366 this intervention would be valuable.
- 367 One concern that has been raised about SMBG is whether to conduct continuous glucose
- 368 monitoring. While we included continuous glucose monitoring and intermittently-scanned
- 369 (commonly known as Flash) glucose monitoring in our definition of SMBG, we excluded studies
- 370 that compared different forms of SMBG, such as studies comparing continuous versus periodic
- 371 SMBG. However, we note that a number of such studies have found SMBG positively associated
- with maternal and neonatal outcomes with continuous monitoring [34-36]; this approach has
- recently been recommended by some for GD [37]. Furthermore, in the context of the COVID-19
- 374 pandemic, possible delays in diagnosis and treatment could result in more advanced disease
- 375 stages; delayed, incomplete or interrupted treatment and increases in behavioral risk factors,
- 376 such as physical inactivity. Self-management actions are prioritized by WHO for maintaining
- 377 essential NCD services during the pandemic.
- 378 Our review has several strengths. We used rigorous methods to search for, extract, grade and
- 379 contextualize the evidence. We also included several outcomes beyond clinical pregnancy
- 380 outcomes, including impact on maternal mental health and quality of life, as well as values and
- 381 preferences and costs data. Together, these provide a more complete picture of the positive and
- 382 negative aspects of this intervention. However, we did not include conference abstracts or grey
- 383literature, and the available peer-reviewed evidence was limited and came almost exclusively
- 384 from high-income countries.

385 Conclusions

- 386 SMBG during pregnancy among individuals with GD is feasible and acceptable, and when
- 387 provided along with a package of interventions including insulin therapy, dietary counseling,
- 388 and ongoing prenatal care with health workers, is generally associated with similar or
- 389 improved maternal and neonatal health outcomes compared with standard care during ANC.
- 390 However, more research is needed in resource-limited settings.

391 2.5 Tables

Study	Location	Population	Sampling	Intervention	Comparator
RCTs					
Crowther 2005 [22]	Australia: 14 centers UK: 4 centers	Women (24-34 weeks gestation) with GD, primiparous, singleton or twin pregnancy Age (mean±sd): 30.9±5.4 (self); 30.1±5.5 (provider) N=490 (self); 510 (provider)	Non- probability facility-based	Glucose self-monitoring (4 times a day) at home, as well as insulin therapy (if required), dietary advice from a dietitian, and ongoing care by attending obstetrical team with physician's support	Routine care at prenatal visits
Landon 2009 [26]	USA: 16 centers	Women (24-31 weeks gestation) with mild GD Age (mean±sd): 29.2±5.7 (self); 28.9±5.6 (provider) N=485 (self); 473 (provider)	Non- probability facility-based	Glucose self-monitoring (daily) at home using a portable memory-based reflectance meter, as well as formal nutritional counseling and diet therapy along with insulin (if required)	Routine care at prenatal visits
Homko 2002 [25]	USA: Philadelphia, PA	Women (<=33 weeks gestation) with GD Age (mean±sd): 30.3±5.4 (self); 29.0±6.4 (provider) N=31 (self); 27 (provider)	Non- probability facility-based	Glucose self-monitoring (4 times a day) at home using a reflectance meter with memory (One Touch Profile)	Routine care at prenatal visits

Table 1. Description of included studies in the effectiveness review (RCTs)

Table 2. GRADE Evidence Profile

			Certainty a	ssessment			№ of p	atients	I	Effect		
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	self- monitoring of blood glucose	clinic blood glucose monitoring	Relative (95% CI)	Absolute (95% CI)	Certainty	Importance
MATEF	RNAL: Hype	rtensive	disorders of pre	gnancy: Pre-e	clampsia			1		1		·
2 [22, 26]	randomised trials	not serious d	not serious	serious ^e	not serious	none	70/966 (7.2%)	118/965 (12.2%)	RR 0.61 (0.46 to 0.81)	48 fewer per 1,000 (from 66 fewer to 23 fewer)	⊕⊕⊕⊖ MODERATE	IMPORTANT
MATEF	RNAL: C-sec	tion: all o	combined									II
3 [22, 25, 26]	randomised trials	not serious d	not serious ^g	serious ^e	not serious	none	291/997 (29.2%)	323/992 (32.6%)	RR 0.92 (0.72 to 1.18)	26 fewer per 1,000 (from 91 fewer to 59 more)	⊕⊕⊕⊖ MODERATE	IMPORTANT
MATEF	RNAL: C-sec	tion: elec	tive C-section o	only	I			1		I		11
1 [22]	randomised trials	not serious d	not serious ^b	serious ^e	serious ^f	none	72/490 (14.7%)	61/510 (12.0%)	RR 1.23 (0.89 to 1.69)	28 more per 1,000 (from 13 fewer to 83 more)	⊕⊕⊖⊖ Low	IMPORTANT
MATEF	RNAL: C-sec	tion: eme	ergency C-section	on only								II
1 [22]	randomised trials	not serious d	not serious ^b	serious ^e	serious ^f	none	80/490 (16.3%)	103/510 (20.2%)	RR 0.81 (0.62 to 1.05)	38 fewer per 1,000 (from 77 fewer to 10 more)	⊕⊕⊖⊖ Low	IMPORTANT

MATERNAL: Preterm labor: Gestational age at delivery in weeks (assessed with: median (IQR))

			Certainty a	ssessment			№ of p	atients	I	Effect		
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	self- monitoring of blood glucose	clinic blood glucose monitoring	Relative (95% CI)	Absolute (95% CI)	Certainty	Importance
1 [22]	randomised trials	not serious d	not serious ^b	serious ^e	not serious	none	490	510	report authors: S 40.0) v 39.3(38.	an(IQR) as ed by study elf: 39.0(38.1- vs Provider: 3-40.4), non- ic test p=0.01	⊕⊕⊕⊖ MODERATE	IMPORTANT
MATEF	RNAL: Prete	erm labor	: Gestational ag	ge at delivery i	n weeks (asses	ssed with: mean	(SD))					
1 [25]	randomised trials	not serious d	not serious ^b	not serious	serious ^c	none	31	27	Mean(SD) as report by study authors: S 38.7(2.4) vs Provid monitoring: 38.4(1 student t-test p=0.		⊕⊕⊕⊖ MODERATE	IMPORTANT
MATEF	RNAL: Prete	rm labor	: Preterm deliv	ery								
1 [26]	randomised trials	not serious d	not serious ^b	serious ^e	serious ^f	none	45/477 (9.4%)	53/455 (11.6%)	RR 0.81 (0.56 to 1.18)	22 fewer per 1,000 (from 51 fewer to 21 more)	⊕⊕⊖⊖ Low	CRITICAL
MATEF	RNAL: Self-e	efficacy (a	assessed with: d	elta score on d	liabetes empo	werment scale be	etween at enr	ollment (<=3	3 weeks G	A) and at 37 w	veeks GA)	
1 [25]	randomised trials	serious ^a	not serious ^b	not serious	serious °	none	31	27	score rep authors: S vs Provie no st significa	SD) of delta orted by study Gelf: 3.9 (12.4) der: 0.2 (7.8), atistically int difference lue >0.05)	⊕⊕⊖⊖ Low	CRITICAL

MATERNAL: Mental health and well-being: Mental health status (follow up: 6 weeks; assessed with: SF-36, score ranges from 0 (worst) to 100 (best))

			Certainty a	ssessment			Nº of p	atients	I	Effect		n I
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	self- monitoring of blood glucose	clinic blood glucose monitoring	Relative (95% CI)	Absolute (95% CI)	Certainty	Importance
1 [22]	randomised trials	serious ^a	not serious ^b	serious ^e	not serious	none	490	510	by study 50.9(9.2) 49.6(10) treatment difference mater race/ethr 1.2 (-0 p=0.1) Outcom Item S General I assesse aspect status/q Reporter relevar (social emotiona health, ar showed t of glu monitorin emotiona a statistica bener	D) as reported authors: Self:) vs Provider: .4), adjusted t effect (mean e, adjusted for ernal age, .icity, parity):).3 to 2.7), 1. Medical es Study 36- Short-Form Health Survey es 8 general s of health uality of life. ed scores for at subscales functioning, l role, mental ad vitality) all rends in favor acose self- g, though only l role showed ally significant fit of self- nitoring.	⊕⊕⊖⊖ Low	IMPORTANT

MATERNAL: Mental health and well-being: Anxiety (follow up: 6 weeks; assessed with: Spielberger State-Trait Anxiety Inventory short form, scores below 15 are considered normal)

			Certainty a	ssessment			№ of p	atients	ŀ	Effect		
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	self- monitoring of blood glucose	clinic blood glucose monitoring	Relative (95% CI)	Absolute (95% CI)	Certainty	Importance
1 [22]	randomised trials	serious ^a	not serious ^b	serious ^e	not serious	none	490	510	by study 11.2(3.7) 11.5(4. treatment difference mate race/ethni	D) as reported authors: Self:) vs Provider: 0), adjusted t effect (mean e, adjusted for ernal age, city, parity): - o 0.2), p=0.17	⊕⊕⊖⊖ Low	IMPORTANT

FETAL/NEWBORN: Birthweight/size for gestational age: Birthweight in grams

3 [22, 25, 26]	randomised trials	not serious d	not serious	serious ^e	not serious	none	1022	1024	MD 125.79 g lower (-175.91 to -75.68)	⊕⊕⊕⊖ MODERATE	IMPORTANT
-------------------	----------------------	---------------------	-------------	----------------------	-------------	------	------	------	--	------------------	-----------

FETAL/NEWBORN: Birthweight/size for gestational age: Large for gestational age (assessed with: >= 90th percentile)

3 [22, 25, 26]	randomised trials	not serious d	not serious	serious ^e	not serious	none	107/1014 (10.6%)	187/1005 (18.6%)	RR 0.58 (0.46 to 0.72)	78 fewer per 1,000 (from 100 fewer to 52 fewer)	⊕⊕⊕⊖ MODERATE	IMPORTANT	
-------------------	----------------------	---------------------	-------------	----------------------	-------------	------	---------------------	---------------------	-------------------------------	---	------------------	-----------	--

FETAL/NEWBORN: Birthweight/size for gestational age: Macrosomia (assessed with: >= 4 kg)

2 [22, 26]	randomised trials	not serious d	not serious	serious ^e	not serious	none	77/983 (7.8%)	175/978 (17.9%)	RR 0.44 (0.34 to 0.57)	100 fewer per 1,000 (from 118 fewer to 77 fewer)	⊕⊕⊕⊖ MODERATE	IMPORTANT
---------------	----------------------	---------------------	-------------	----------------------	-------------	------	------------------	--------------------	-------------------------------	--	------------------	-----------

FETAL/NEWBORN: Shoulder dystocia

			Certainty a	ssessment			№ of p	atients	Ι	Effect		
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	self- monitoring of blood glucose	clinic blood glucose monitoring	Relative (95% CI)	Absolute (95% CI)	Certainty	Importance
2 [22, 26]	randomised trials	not serious d	not serious	serious ^e	not serious	none	14/982 (1.4%)	34/979 (3.5%)	RR 0.41 (0.22 to 0.76)	20 fewer per 1,000 (from 27 fewer to 8 fewer)	⊕⊕⊕⊖ MODERATE	IMPORTANT

FETAL/NEWBORN: Stillbirth

2 [22, 26]		not serious d	not serious	serious ^e	serious ^{h,i}	none	0/991 (0.0%)	1/997 (0.1%)	RR 0.52 (0.07 to 3.81)	0 fewer per 1,000 (from 1 fewer to 3 more)	⊕⊕⊖⊖ Low	CRITICAL	
---------------	--	---------------------	-------------	----------------------	------------------------	------	-----------------	-----------------	-------------------------------	--	-------------	----------	--

FETAL/NEWBORN: Respiratory distress syndrome

3 [22, 25, 26]	randomised trials	not serious d	not serious	serious ^e	very serious	none	37/1014 (3.6%)	33/1006 (3.3%)	RR 1.09 (0.62 to 1.91)	3 more per 1,000 (from 12 fewer to 30 more)	⊕⊖⊖⊖ VERY LOW	CRITICAL	
-------------------	----------------------	---------------------	-------------	----------------------	--------------	------	-------------------	-------------------	-------------------------------	---	------------------	----------	--

HEALTHCARE UTILIZATION: Follow-up care with appropriate management: Number of visits to a health worker (assessed with: total count of antenatal clinic visits after enrollment, including routine ANC visits, possibly but not necessarily prompted by blood glucose monitoring monitoring)

1 [22]	randomised trials	not serious	not serious ^b	serious ^e	not serious	none	490	510	Median (IQR) reported by study authors: Self:		CRITICAL
	unans	d							5.0 (1-7) vs Provider:	MODERATE	
									5.2 (3-7), non-		
									parametric test p<0.001		
											l

HEALTHCARE UTILIZATION: Follow-up care with appropriate management: Number of visits to a health worker (assessed with: total count of physician clinic visits after enrollment, potentially including routine ANC visits, possibly but not necessarily prompted by blood glucose monitoring monitoring)

			Certainty a	ssessment			№ of p	atients	Effect			
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	self- monitoring of blood glucose	clinic blood glucose monitoring	Relative (95% CI)	Absolute (95% CI)	Certainty	Importance
1 [22]	randomised trials	not serious d	not serious ^b	serious ^e	not serious	none	490	510	by study a (1-7) vs H 2), non-p	IQR) reported authors: Self: 3 Provider: 0 (0- arametric test <0.001	⊕⊕⊕⊖ MODERATE	CRITICAL

HEALTHCARE UTILIZATION: Follow-up care with appropriate management: Visits to a health worker (assessed with: Visit with a dietitian yes/no)

1 [22]	randomised trials	not serious d	not serious ^b	serious ^e	not serious	none	453/490 (92.4%)	51/510 (10.0%)	RR 9.24 (7.12 to 12.01)	824 more per 1,000 (from 612 more to 1,000 more)	⊕⊕⊕⊖ MODERATE	CRITICAL	
--------	----------------------	---------------------	--------------------------	----------------------	-------------	------	--------------------	-------------------	--------------------------------	--	------------------	----------	--

HEALTHCARE UTILIZATION: Follow-up care with appropriate management: Visits to a health worker (assessed with: Visit with a diabetes educator yes/no)

HEALTHCARE UTILIZATION: Follow-up care with appropriate management: Antenatal admission

1 [22]	randomised trials	not serious d	not serious ^b	serious ^e	serious ^f	none	141/490 (28.8%)	139/510 (27.3%)	RR 1.06 (0.87 to 1.29)	16 more per 1,000 (from 35 fewer to 79 more)	⊕⊕⊖⊖ Low	CRITICAL	
--------	----------------------	---------------------	--------------------------	----------------------	----------------------	------	--------------------	--------------------	-------------------------------	--	-------------	----------	--

Table 3. Description of studies representing values and preferences data

Study	Location	Population and sample size	Data collection method	SMBG description
Ardilouze et al., 2019 [27]	Canada	Pregnant women and other pregnant people ages 18+ years, with singleton pregnancy, 24-28-weeks gestation, 50 g GLT ≥7.2 mmol/L (GLT+), who were receiving pre- and perinatal care and did not have pre- pregnancy diabetes, disease or treatment with implications for glucose metabolism N=103	Questionnaires	Self-monitoring with a calibrated glucometer used after fasting and 2 hours postpradially, over 7 consecutive days without modifications to diet or exercise habits. Patients recorded their glucose levels on paper and transmitted them to the study nurse via e-mail or fax the day after the 7 th day of measurements. They subsequently received questionnaires which were returned before diagnoses were announced to patients.
Garnweidner- Holme et al., 2018 and Skar et al., 2018 [28, 31] Pregnant+	Norway	Midwives (n=6) and nurses specializing in diabetes care (n=3) working at the diabetes outpatient clinic with a large population of women from diverse ethnic backgrounds; N=9 [28] Pregnant women and other pregnant people of either ethnic Norwegian (n= 10) or immigrant backgrounds (i.e. born outside Norway and residing in Norway at the time of the study) (n= 7); N=17 [31]	Semi-structured interviews using the intervention group participants from a parent RCT (Pregnant+)	Self-monitoring by recording blood glucose levels accompanied by receiving verbal and written health and nutrition information, in line with clinic-based standard care protocol for GD. The parent RCT added a use of a culture-sensitive mobile phone application to the standard care protocol. Patients could create their own profiles consisting of information related to but not limited to: their outpatient clinic, pre- pregnancy anthropometric measurements and physical activity level and preferred food culture. Patients could also record their physical activity time. Caregivers were requested to refrain from using the application to communicate as part of consultation.
Hirst et al., 2015 [29]	United Kingdom	Pregnant women and other pregnant people, with singleton pregnancy, whose GD was	Structured questionnaires	Self-monitoring using a Bluetooth-enabled glucometer (Polymap Glucose meter accessory with Lifescan UltraEasy meter) which automatically transmitted finger-prick blood

		diagnosed prior to the 34 th week of gestation, and having not received pharmacological therapy after 1 week of BG monitoring N=49		glucose level readings to a secure website via a smartphone application. Patients could label the readings with information regarding meals and medication use. The record was reviewed at least 3 times a week by caregiver team; patients and the team could communicate using the application. All equipment was loaned for free.
Rigla et al., 2018 [30]	Spain	Pregnant women and other pregnant people of greater than 19 years of age with GD diagnosed before the 34^{th} week of gestation, having familiarity with smartphones and computer technology in general, and no history of pre- gestational diabetes, hemoglobin A1c >6.5%, active treatment with implications for changes in blood glucose levels, blindness, or severe mental disturbances N=19	Questionnaires	Self-monitoring using a smartphone with the clinical data collection and messaging system, including an accelerometer, Bluetooth-enabled glucometer (Accu-Chek Aviva Connect, Roche Diagnostics GmbH, Mannheim, Germany), Bluetooth- enabled blood pressure monitor (Bluetooth Blood Pressure Monitor 708-BT, Omron Healthcare Co, Ltd, Kyoto, Japan), and mechanism with which to report on the results of fasting daily ketonuria determination. When it comes to the blood glucose level monitoring, patients were requested to download their readings (fasting and 1- hour postprandial) from the glucometer every 3 days. Patients were also requested to continue with their in-person visits to the clinic.
Youngwanichsetha et al., 2016 [32]	Thailand	Pregnant women and other pregnant people with GD diagnosed during 24- to 30- week gestation treated in the antenatal care units, diabetes clinics, or obstetric wards. N=30	Semi-structured interviews	Pregnant women and other pregnant people with GD were assumed to practice self-monitoring four times a day with a glucometer, as standard clinical practice in this hospital. The patients were to record the readings on paper or keep in the device memory.

392 3 Declarations

393 3.1 Ethics approval and consent to participate

394 Ethical approval and patients' consent to participate was not required for this systematic review, since 395 all data came from published articles.

396 3.2 Consent for publication

397 Not required, since all data came from published articles.

398 **3.3** Availability of data and materials

399 Extracted data are available on request to the corresponding author.

400 **3.4 Competing interests**

401 The authors declare that the research was conducted in the absence of any commercial or financial 402 relationships that could be construed as a potential conflict of interest.

403 **4** Author Contributions

- 404 MN and OT conceptualized the study. CEK and PTY designed the protocol with feedback from OT,
- 405 RG, BL, CZ and MN. PTY ran the database search and oversaw search, screening, full text review,
- 406 and data abstraction processes with support from DR. CEK and PTY performed data analysis. PTY,
- 407 CEK, and CZ drafted the manuscript. All authors reviewed the draft, provided critical review, and
- 408 read and approved the final manuscript. The corresponding author, as guarantor, accepts full
- responsibility for the finished article has access to any data and controlled the decision to publish.
 The corresponding author attests that all listed authors meet the authorship criteria and that no others
- 411 meeting the criteria have been omitted.
- 412 The named authors alone are responsible for the views expressed in this publication and do not
- 413 necessarily represent the decisions or the policies of the World Health Organization (WHO) or the
- 414 UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and
- 415 Research Training in Human Reproduction (HRP).
- 416 The corresponding author, as guarantor, affirms that the manuscript is an honest, accurate, and
- 417 transparent account of the study being reported; that no important aspects of the study have been
- 418 omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been
- 419 explained.

420 5 Funding

- 421 We gratefully acknowledge financial support of The Children's Investment Fund Foundation (CIFF).
- 422 The funder played no part in the decision to submit the article for publication, nor in the collection,
- 423 analysis and interpretation of data. All authors had full access to all of the data in the study and can
- 424 take responsibility for the integrity of the data and the accuracy of the data analysis.

425 6 Acknowledgments

- 426 We thank Laura Ferguson, University of Southern California, and Maurice Bucagu, Department of
- 427 Maternal, Child and Adolescent Health, World Health Organization, for their feedback on the review
- 428 protocol and Bianca Hemmingson, Department of Non-Communicable Diseases, World Health
- 429 Organization, for her feedback on the interpretation of the review findings. We also thank our
- 430 research assistants from the Johns Hopkins Bloomberg School of Public Health (Jaime Marquis,
- 431 Sarah Wagner, and Xuhao Yang) for their help in screening citations and abstracting data.

7 References

1. WHO. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation, Part 1. Geneva, Switzerland: World Health Organization; 1999.

2. WHO. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. Geneva, Switzerland: World Health Organization; 2013.

3. American Diabetes Association. 14. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2021. Diabetes care. 2021;44(Supplement 1):S200.

4. Metzger BE, Buchanan TA, Coustan DR, de Leiva A, Dunger DB, Hadden DR, et al. Summary and Recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes care. 2007;30(Supplement 2):S251.

5. International Diabetes Federation. IDF GDM Model of Care. Implementation protocol. Guidelines for healthcare professionals. Brussels, Belgium: IDF; 2017.

6. WHO. WHO consolidated guideline on self-care interventions for health: sexual and reproductive health and rights. Geneva, Switzerland: World Health Organization; 2019.

7. WHO. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. Geneva, Switzerland: World Health Organization; 2011.

8. WHO. WHO recommendations on antenatal care for a positive pregnancy experience. Geneva, Switzerland: World Health Organization; 2017.

9. WHO. WHO package of essential noncommunicable (PEN) disease interventions for primary health care. Geneva, Switzerland: World Health Organization; 2020.

10. WHO. Maintaining essential health services: operational guidance for the COVID-19 context interim guidance. Geneva, Switzerland: World Health Organization; 2020.

11. WHO. WHO handbook for guideline development. 2nd ed ed. Geneva: World Health Organization; 2014 2014.

12. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical research ed). 2021;372:n71.

13. De Block C, Vertommen J, Manuel-y-Keenoy B, Van Gaal L. Minimally-invasive and noninvasive continuous glucose monitoring systems: indications, advantages, limitations and clinical aspects. Current diabetes reviews. 2008;4(3):159-68.

14. Hoeks LB, Greven WL, de Valk HW. Real-time continuous glucose monitoring system for treatment of diabetes: a systematic review. Diabetic medicine : a journal of the British Diabetic Association. 2011;28(4):386-94.

15. Lau Y, Htun TP, Wong SN, Tam WS, Klainin-Yobas P. Efficacy of Internet-Based Self-Monitoring Interventions on Maternal and Neonatal Outcomes in Perinatal Diabetic Women: A Systematic Review and Meta-Analysis. Journal of medical Internet research. 2016;18(8):e220.

16. Negrato CA, Zajdenverg L. Self-monitoring of blood glucose during pregnancy: indications and limitations. Diabetology & metabolic syndrome. 2012;4(1):54-.

17. Xie W, Dai P, Qin Y, Wu M, Yang B, Yu X. Effectiveness of telemedicine for pregnant women with gestational diabetes mellitus: an updated meta-analysis of 32 randomized controlled trials with trial sequential analysis. BMC pregnancy and childbirth. 2020;20:1-14.

18. Raman P, Shepherd E, Dowswell T, Middleton P, Crowther CA. Different methods and settings for glucose monitoring for gestational diabetes during pregnancy. Cochrane Database of Systematic Reviews. 2017;2017(10).

19. Cochrane Handbook for Systematic Reviews of Interventions 2019. Available from: www.training.cochrane.org/handbook.

20. Kennedy CE, Fonner VA, Armstrong KA, Denison JA, Yeh PT, O'Reilly KR, et al. The Evidence Project risk of bias tool: assessing study rigor for both randomized and non-randomized intervention studies. Systematic Reviews. 2019;8(1):3.

21. Bělobrádková J, Filipenský B, Roztocil A, Horký P, Janků K, Pilka L, et al. [The effect of self-monitoring on perinatal outcome in insulin therapy of diabetic women during pregnancy]. Vnitrni lekarstvi. 1992;38(11):1077-81.

22. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. The New England journal of medicine. 2005;352(24):2477-86.

23. Espersen T, Klebe JG. Self-monitoring of blood glucose in pregnant diabetics. A comparative study of the blood glucose level and course of pregnancy in pregnant diabetics on an out-patient regime before and after the introduction of methods for home analysis of blood glucose. Acta obstetricia et gynecologica Scandinavica. 1985;64(1):11-4.

24. Hawkins JS, Casey BM, Lo JY, Moss K, McIntire DD, Leveno KJ. Weekly compared with daily blood glucose monitoring in women with diet-treated gestational diabetes. Obstetrics and gynecology. 2009;113(6):1307-12.

25. Homko CJ, Sivan E, Reece EA. The impact of self-monitoring of blood glucose on selfefficacy and pregnancy outcomes in women with diet-controlled gestational diabetes. The Diabetes educator. 2002;28(3):435-43.

26. Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. The New England journal of medicine. 2009;361(14):1339-48.

27. Ardilouze A, Bouchard P, Hivert MF, Simard C, Allard C, Garant MP, et al. Self-Monitoring of Blood Glucose: A Complementary Method Beyond the Oral Glucose Tolerance Test to Identify Hyperglycemia During Pregnancy. Canadian journal of diabetes. 2019;43(8):627-35.

28. Garnweidner-Holme L, Hoel Andersen T, Sando MW, Noll J, Lukasse M. Health Care Professionals' Attitudes Toward, and Experiences of Using, a Culture-Sensitive Smartphone App for Women with Gestational Diabetes Mellitus: Qualitative Study. JMIR mHealth and uHealth. 2018;6(5):e123.

29. Hirst JE, Mackillop L, Loerup L, Kevat DA, Bartlett K, Gibson O, et al. Acceptability and user satisfaction of a smartphone-based, interactive blood glucose management system in women with gestational diabetes mellitus. Journal of diabetes science and technology. 2015;9(1):111-5.

30. Rigla M, Martínez-Sarriegui I, García-Sáez G, Pons B, Hernando ME. Gestational Diabetes Management Using Smart Mobile Telemedicine. Journal of diabetes science and technology. 2018;12(2):260-4.

31. Skar JB, Garnweidner-Holme LM, Lukasse M, Terragni L. Women's experiences with using a smartphone app (the Pregnant+ app) to manage gestational diabetes mellitus in a randomised controlled trial. Midwifery. 2018;58:102-8.

32. Youngwanichsetha S, Phumdoung S. Lived experience of blood glucose self-monitoring among pregnant women with gestational diabetes mellitus: a phenomenological research. Journal of clinical nursing. 2017;26(19-20):2915-21.


33. Goldstein A, Elliott J, Lederman S, Worcester B, Russell P, Linzey EM. Economic effects of self-monitoring of blood glucose concentrations by women with insulin-dependent diabetes during pregnancy. The Journal of reproductive medicine. 1982;27(8):449-50.

34. De Valk HW. First nationwide real-life results on the efficacy of real-time continuous glucose monitoring in the Netherlands: The tracing study. Endocrine Reviews. 2015;36.

35. Kestilä KK, Ekblad UU, Rönnemaa T. Continuous glucose monitoring versus self-monitoring of blood glucose in the treatment of gestational diabetes mellitus. Diabetes research and clinical practice. 2007;77(2):174-9.

36. Lane AS, Mlynarczyk MA, de Veciana M, Abuhamad AZ, Green LM, Baraki DI. Real-Time Continuous Glucose Monitoring in Gestational Diabetes: A Randomized Controlled Trial. American Journal of Perinatology. 2019;36(9):891-7.

37. Yamamoto JM, Corcoy R, Donovan LE, Stewart ZA, Tomlinson G, Beardsall K, et al. Maternal glycaemic control and risk of neonatal hypoglycaemia in Type 1 diabetes pregnancy: a secondary analysis of the CONCEPTT trial. Diabetic medicine : a journal of the British Diabetic Association. 2019;36(8):1046-53.




Pre-eclampsia A.

Study name		Statis	stics for ea	ach study			Risk r	atio and	95% Cl
	Risk ratio	Lower limit	Upper limit	p-Value	Z-Value				
Crowther 2005	0.649	0.479	0.879	0.005	-2.790	1			
Landon 2009	0.459	0.233	0.902	0.024	-2.258		-		
	0.612	0.464	0.808	0.001	-3.470			•	
						0.01	0.1	1	10
C-section									
Study name		Statis	stics for ea	ach study			<u>Risk r</u>	atio and	95% Cl
	Risk ratio	Lower limit	Upper limit	Z-Value	p-Value				
Crowther 2005	0.965	0.804	1.158	-0.386	0.699	T	Ĩ		- T
Landon 2009	0 794	0.653	0 967	-2 300	0.021				

Β.

<u>Otday name</u>		Statis		ion Study	
	Risk ratio	Lower limit	Upper limit	Z-Value	p-Value
Crowther 2005	0.965	0.804	1.158	-0.386	0.699
Landon 2009	0.794	0.653	0.967	-2.300	0.021
Homko 2002	1.916	0.762	4.821	1.381	0.167
	0.921	0.722	1.175	-0.660	0.509



100

Birthweight in grams C.

Study name			Statistics	for each stu	dy			
	Difference in means	Standard error	Variance	Lower limit	Upper limit	p-Value	Z-Value	
Crowther 2005	-147.000	37.951	1440.270	-221.382	-72.618	0.000	-3.873	
Landon 2009	-106.000	35.354	1249.895	-175.292	-36.708	0.003	-2.998	
Homko 2002	-157.400	168.836	28505.500	-488.312	173.512	0.351	-0.932	
	-125.791	25.570	653.824	-175.908	-75.675	0.000	-4.919	

D. Large for gestational age

	Study name		Statis	stics for ea	ach study			Risk ratio and 95% CI			
		Risk ratio	Lower limit	Upper limit	p-Value	Z-Value					
	Crowther 2005	0.612	0.466	0.805	0.000	-3.511	1	1			
	Landon 2009	0.490	0.331	0.727	0.000	-3.552			-		
	Homko 2002	0.726	0.249	2.113	0.557	-0.588					
		0.575	0.462	0.717	0.000	-4.927		0.0	•	2	
							0.01	0.1	1	10	100
Ε.	Macrosomia		Ctatic	tion for a	ala atudu			Dieke	atia and	059/ 01	
	Study name		Statis	stics for ea	ach study			RISK	atio and	95% CI	


	Risk ratio	Lower limit	Upper limit	p-Value	Z-Value
Crowther 2005	0.461	0.337	0.631	0.000	-4.834
Landon 2009	0.410	0.268	0.627	0.000	-4.121
	0.442	0.344	0.569	0.000	-6.338



Shoulder dystocia Study name F.

Study name	Statistics for each study								
	Risk ratio	Lower limit	Upper limit	p-Value	Z-Value				
Crowther 2005	0.453	0.188	1.092	0.078	-1.764				
Landon 2009	0.372	0.157	0.882	0.025	-2.246				
	0.410	0.221	0.759	0.005	-2.839				

Risk ratio and 95% CI




Stillbirth G.

	Study name		Statis				
		Risk ratio	Lower limit	Upper limit	p-Value	Z-Value	
	Crowther 2005	0.335	0.014	8.222	0.503	-0.669	-

Risk ratio and 95% Cl







Risk ratio and 95% CI

H. Respiratory distress syndrome

Study name	Statistics for each study					
medRxiv preprint doi: https://doi.org/10.1101/2022.08.11.22278238; this version pos (which was not certified by peer review) is the author/funder, who has granted It is made available under a CC-BY-NC-ND 4.0	Risk sted August 11, 2022. d med Richard incense to International incense	Lower The copyright holder for display the preprint in p	Upper this preprint perpetulty mit	p-Value	Z-Value	
Crowther 2005	1.472	0.829	2.613	0.187	1.319	
Landon 2009	0.660	0.285	1.530	0.333	-0.968	
Homko 2002	0.871	0.057	13.266	0.921	-0.099	
	1.085	0.617	1.908	0.776	0.284	

